Alan Goldberg, MD
Cardiovascular Disease · Chicago, ILNPI 1235578550
Payments from drug & device makers
Across 6 payments — averaging $31.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atricure, Inc.$62
- Bard Peripheral Vascular, Inc.$50
- Abiomed$32
- Abbott$25
- Boston Scientific$13
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9
What the payments were for
- Speaking & faculty fees$5026%
- Food & beverage$14274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atricure, Inc. | 1 | $62 |
| Bard Peripheral Vascular, Inc. | 1 | $50 |
| Abiomed | 1 | $32 |
| Abbott | 1 | $25 |
| Boston Scientific | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $9 |
How this compares
$192 in reported general payments places this provider in the 15th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 13 | $298,346 |
| EliquisApixaban | 109 | $166,559 |
| EntrestoSacubitril/Valsartan | 66 | $91,879 |
| XareltoRivaroxaban | 61 | $61,513 |
| Repatha SureclickEvolocumab | 42 | $56,086 |
| JardianceEmpagliflozin | 43 | $48,670 |
| Praluent PenAlirocumab | 38 | $33,824 |
| FarxigaDapagliflozin Propanediol | 20 | $23,778 |
| Ezetimibe | 180 | $5,778 |
| Atorvastatin Calcium | 440 | $4,510 |
| Rosuvastatin Calcium | 221 | $4,407 |
| Metoprolol Succinate | 271 | $3,966 |
| Carvedilol | 248 | $2,651 |
| Bumetanide | 42 | $2,205 |
| Carvedilol ErCarvedilol Phosphate | 11 | $1,881 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chicago
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Nitasha SarswatChicago$2M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
- Boaz AvitallChicago$663K
- Ravi PatelChicago$488K
- Lubna ChoudhuryChicago$476K
- Akhil NarangChicago$427K
- Amit AminChicago$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.